Compare AbbVie Inc (ABBV) vs First Solar, Inc. (FSLR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs First Solar, Inc. — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while First Solar, Inc. trades at $224.16 (market cap $24.47B). The key difference: AbbVie Inc is far larger — about 18.4× First Solar, Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | FSLR | |
|---|---|---|
Market Cap | $449.91B | $24.47B |
Sector | Health | Technology |
52-Week High | $261.07 | $318.30 |
52-Week Low | $184.85 | $160.84 |
Enterprise Value | $513.38B | $22.63B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
First Solar (FSLR) trades at $227.72, up 1.4% with a bearish technical signal despite strong fundamentals. The company shows robust financial performance with $5.22B revenue, 30.73% net margin, and positive cash flow trends. Recent earnings beat expectations in Q1 2026 but missed in previous quarters. Multiple class action lawsuits create significant headwinds, though Deutsche Bank recently upgraded the stock citing valuation discount.
The stock presents a valuation opportunity with P/E of 15.06 below industry averages, but legal risks and technical weakness suggest cautious optimism. Analyst consensus price target of $272.20 implies 19.5% upside potential, though investors must weigh strong profitability against ongoing litigation concerns and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →
